Dr. Lok Chung Chan is a Chairman at Vesigen, Inc., a Chairman at Apellis Pharmaceuticals, Inc., a Member-Global Advisory Council at The International Society for Stem Cell Research, a Chairman at Stealth BioTherapeutics Corp., a Chairman at Morningside Group Ltd., a Chairman at The Chinese University of Hong Kong, a Chairman-Overseers Board at Morningside College, a Member at Massachusetts General Hospital Cancer Center and a Member-International Governors Board at New York Academy of Sciences.
He is on the Board of Directors at LumiraDx Ltd., The Scripps Research Institute, Stealth BioTherapeutics, Inc., Hang Lung Group Ltd., Canopy Education, Inc., MatriVAX, Inc., Morningside Foundation, Synchroneuron, Inc., Vaccine Technologies, Inc. and Fudan University. Dr. Chan was previously employed as an Independent Director by Aduro BioTech, Inc., a Co-Founder by Morningside Group Ltd. (United States), a Co-Founder by Morningside Venture Investments Ltd., a Member by Council on Foreign Relations, Inc., and a Non-Executive Director by NuCana Plc.
He also served on the board at PhoreMost Ltd., Natural Polymer International Corp., Advanced Cell Diagnostics, Inc., Critical Biologics Corp., Inimex Pharmaceuticals, Inc., InSilixa, Inc., Kezar Life Sciences, Inc., MetaCure (USA), Inc., Oxyrane UK Ltd. and Serica Technologies, Inc.
He received his undergraduate degree from the University of California, Los Angeles, a graduate degree from the University of California, Los Angeles, a graduate degree from Harvard University and a doctorate degree from Harvard University.